Abstract
Introduction
Compared with bare-metal stents (BMS), drug-eluting stents (DES) have shown better clinical outcomes for patients undergoing percutaneous coronary intervention (PCI) by potent prevention from neointimal hyperplasia [1] . However, earlygeneration DES produced late thrombotic events, more than 1-year, by delaying arterial healing of stented vessels [2] [3] [4] [5] . New-generation DES have developed with thinner stent struts, more biocompatible polymer coatings for drug release, and a variety of antiproliferative agents [6] . This development has led to a significant improvement in the efficacy and safety of early-generation DES. In recent years, new-generation DES replaced early-generation DES because of improved stent design, similar or superior anti-restenotic efficacy, and consistently lower rates of late stent thrombosis (ST) [7, 8] . In fact, currently used DES is a standard treatment in modern clinical procedures and is used by most patients undergoing PCI.
Currently, thin strut and durable polymerbased zotarolimus-eluting stent (ZES) and everolimus-eluting stent (EES) are widely used. Resolute Onyx-ZES (O-ZES), the latest version of ZES, has thinner strut, 81 µm, than Resolute-ZES (R-ZES), prior version of ZES, which had 91 µm of strut thickness. R-ZES and EES have been directly compared in several randomized trials powered for non-inferiority with respect to composite clinical endpoints [9] [10] [11] . However, there are few studies to compare the safety and efficacy of O-ZES and EES in patients with acute myocardial infarction (AMI). Therefore, the present study aimed to compare clinical outcomes of O-ZES and EES in patients with AMI undergoing successful PCI.
Methods

Study design and patient population
The Korea Acute Myocardial Infarction Registry (KAMIR) is a prospective multicenter registry providing observational online data collected and designed to examine characteristics, treatment practices, and outcomes in patients presenting AMI with the support of the Korean Circulation Society [12] .
Study protocols were approved by the ethics committee at each participating center, and followed principles of the Declaration of Helsinki. (Fig. 1 ).
Study endpoints, definitions, and interventional procedures
The primary endpoint was target lesion failure (TLF), being defined as a composite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemic driven-target lesion revascularization (ID-TLR) at 6 months clinical follow-up. The secondary endpoints were individual components of the TLF and definite/probable ST as defined by the Academic Research Consortium [13] .
Death was regarded as cardiac in origin unless obvious non-cardiac causes could be identified. Myocardial infarction (MI) was defined as either the development of new pathological Q waves ≥ 0.04 s in duration in ≥ 2 contiguous leads or an elevation of creatine phosphokinase levels to > 2 times normal with positive creatine phosphokinase-MB or troponin I or T levels. TV-MI was defined as MI attributable to target vessel. TLR was considered ischemic-driven if associated with a positive functional study, a target lesion stenosis ≥ 50% by core laboratory quantitative analysis with ischemic symptoms or a target lesion stenosis ≥ 70% with or without documented ischemia.
Hypertension was defined as a history of hypertension diagnosed and treated with medication, diet and/or exercise, or blood pressure > 140 mmHg systolic or 90 mmHg diastolic on at least two occasions, or currently on antihypertensive pharmacologic therapy. Diabetes mellitus (DM) was defined as a history of DM, regardless of duration of disease, need for antidiabetic agents, or a fasting blood glucose > 126 mg/dL. Family history of ischemic heart disease was indicated if the patient had any direct blood relatives (parents, siblings, children) who had any of the preceeding, which were diagnosed at age < 55 years.
All patients who underwent PCI received 300 mg acetylsalicylic acid (ASA) and 300 or 600 mg clopidogrel, or prasugrel 60 mg, or ticagrelor 180 mg as a loading dose prior to PCI. After PCI, Yongcheol Kim et al., Efficacy and safety of Resolute Onyx TM in AMI 100-300 mg ASA and 75 mg clopidogrel, or 5 or 10 mg prasugrel one daily or 90 mg ticagrelor twice daily were prescribed for maintenance dose. Medication such as beta-blocker, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and statin were prescribed during hospitalization and after discharge. Coronary artery angiography and stent implantation were performed by standard methods. The selection of PCI timing, medication, vascular access, use of glycoprotein IIb/IIIa inhibitor, use of coronary stents were at physician discretion. Clinical follow-up was done at 6 months after enrollment.
Statistical analysis
All continuous variables were expressed as the mean with standard deviation (SD) or median with interquartile ranges (IQR), when appropriate. All categorical variables were reported as numbers with percentages. The continuous variables were compared using the unpaired t-test or Mann-Whitney U test, as appropriate. The categorical variables were analyzed by using a c 2 test or Fisher's exact test. The Cox proportional hazard regression modeling (with adjustment for covariates) was used to assess clinical outcomes. A Kaplan-Meier analysis was performed on data from the O-ZES and EES patient groups to compare 6-month TLF and cardiac death, and the difference was determined using a log-rank test. Variables had significance in univariate analysis (p < 0.100) for endpoints which were included in multivariate analysis. The following variables were included in multivariate Cox regression analysis: age ≥ 65, body mass index ≥ 25 kg/m 2 , hypertension, DM, dyslipidemia, family history of ischemic heart disease, history of MI, history of angina, history of heart failure, history of cerebrovascular accident, Killip classification III/IV, left ventricular ejection fraction ≤ 50%, left main or multivessel disease, image-guided PCI, ACC/ /AHA B2/C lesion, pre Thrombolysis In Myocardial Infarction (TIMI) flow grade 0/1.
All analyses were two-tailed, and p value < 0.05 was considered to reflect significance. All statistical analyses were performed using SPSS for Windows software (ver. 21.0; SPSS Inc., Chicago, IL, USA).
Results
A total of 1,486 patients with AMI underwent successful PCI were included in the present study. The average age of the total population was 64.1 ± ± 12.3 years and 75.4% were men. The mean stent diameter was 3.14 ± 0.44 mm and the mean stent length was 30.6 ± 15.1 mm. The average number of stents used per vessel was 1.22 ± 0.45.
Baseline characteristics and coronary angiographic findings
Mean age was similar for the O-ZES and EES group (64.2 ± 12.2 vs. 64.0 ± 12.4, p = 0.802). The O-ZES group had higher prevalence of past his- tory of MI when compared with EES group (7.5% vs. 4.2%, p = 0.010). In laboratory findings, there were no significant differences in either group. In terms of procedural characteristics, pre-PCI TIMI flow grade 0/1 was higher in O-ZES group than in EES group (59.5% vs. 53.2%, p = 0.028). In angiographic findings, O-ZES group more frequently had left main or multivessel disease than in EES group (56.7% vs. 49.0%, p = 0.008). ACEI/ARB was less prescribed in the O-ZES group than in the EES group (73.6% vs. 78.9%, p = 0.032) (Tables 1, 2 ).
Six-month clinical outcomes
The 6-month clinical outcomes did not differ between the two groups as shown in Table 3 . In Cox proportional hazard analysis, O-ZES also showed no statistical differences in the incidence of TLF (4.0% vs. 3.9%, adjusted hazard ratio [HR] 1.17, 95% confidential interval [CI] 0.58-2.35, p = 0.665) ( Fig. 2A) , cardiac death (3.7% vs. 3.4%, adjusted HR 1.25, 95% CI 0.59-2.63, p = 0.560) (Fig. 2B) , TV-MI (0.2% vs. 0.6%, adjusted HR 0.56, 95% CI 0.07-4.85, p = 0.600), ID-TLR (0.0% vs. 0.3%, (Table 3) .
Discussion
There have been no studies to directly compare clinical outcomes between O-ZES and EES in specific high-risk groups, such as patients with AMI. This is the first multicenter and currently the largest observational study investigating clinical outcomes of AMI patients undergoing successful PCI with O-ZES or EES. The present study demonstrates that implantation of O-ZES or EES provided similar short-term clinical outcomes in patients with AMI undergoing successful PCI.
There are several studies regarding a comparison of clinical outcomes after PCI with R-ZES. In the RESOLUTE All Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent with an Everolimus-Eluting Stent for Percutaneous Coronary Intervention), compared with the EES, the TLF did not significantly differ between R-ZES and EES in complex patients, such as AMI (8.9% in R-ZES group vs. 9.7% in EES group, p = 0.66) at 1-year follow-up [14] . In another randomized TWENTE trial, complex patients treated with R-ZES and EES showed similar TLF during 2-year follow-up (11.7% in R-ZES group vs. 10.9% in EES group, p = 0.68) [15] . In these two randomized trials, however, patients with AMI were only 43.6% and 37.1%, respectively, when compared with the [16] . In the RESOLUTE Global Clinical Trial Program comprising 10 prospective trials, R-ZES showed good long-term clinical outcomes.
In 7618 patients treated with R-ZES, the 5-year cumulative incidence of TLF was 13.4%, cardiac death 5.0%, TV-MI 4.4%, and ID-TLR 6.3% [17] .
In the RESOLUTE Global Clinical Trial Program, STEMI patients treated with R-ZES also had good 3-year clinical outcomes, including TLF 9.8%, cardiac death 2.9%, TV-MI 1.6%, ID-TLR 7.0%, and definite/probable ST 2.8% [16] .
Regarding the safety and efficacy of O-ZES, O-ZES showed 1-year TLF rate of 4.4% and similar efficacy and safety compared with most contemporary DES [18] . O-ZES demonstrated superiority for 8-month in-stent late lumen loss compared with the historical control R-ZES in the RESOLUTE ONYX core trial (0.24 ± 0.39 mm with O-ZES vs. 0.36 ± 0.52 mm with R-ZES, p = 0.029) [19] . Moreover, 2.0 mm O-ZES was associated with a low rate of TLF and late lumen loss without definite/ probable ST at 12 month follow-up for treatment of coronary lesions with a very small reference vessel diameter, less than 2.25 mm in the recent study [20] . These favorable clinical outcomes including angiographic benefit of O-ZES could be explained by characteristics of O-ZES. O-ZES has a swaged shape and a larger strut width-to-thickness ratio (strut width 91 µm and thickness 81 µm) to maintain radial strength despite thinner strut when compared with R-ZES. O-ZES also has a dense inner core composed of the platinum-iridium alloy for increased radiopacity. The enhanced radiopacity of O-ZES might have contributed to less geographic miss which was associated with increased target vessel revascularization [21] .
Limitations of the study There were several limitations in the present study. First, it was a retrospective study and there were possibilities for selection bias. Therefore multivariate analysis was undertaken to overcome these limitations. Secondly, the number of patients included in O-ZES group was relatively small, and thus, this study is less robust because of the small sample size. Thirdly, EES group included durable polymer everolimus-eluting stent (XIENCE TM ) and bioresorbable polymer everolimus-eluting stent (SYNERGY TM ). Differing stent features can be a possible confounding factor. Finally, interval of follow-up was too short to analyze long-term clinical outcomes. Thus, more extensive and long-term data are needed.
Conclusions
This study shows that implantation of O-ZES or EES provided similar clinical outcomes with similar risk of 6-month TLF and definite/probable ST in patients with AMI undergoing successful PCI.
